East Coast Research discussion, page-7

The model can definitely help, just need to be able to pick it apart rather than to trust it blindly. Applying a constant growth rate is also probably not best as it ignores all the growth that'll come in the first few years due to the base effect.

By main issue as well is this model assumes the MIGS market remains the same and grows at the same rate, when in reality it is quite clear that MIGS is rapidly moving into the spotlight (in the US at least but probably globally down the track) as a standard of care for glaucoma, particularly earlier on in the disease stage (meaning all glaucoma sufferers will be potential customers, not just the few that progress to more advanced stage). Not to mention the fact that iTrack Advance can complement other procedures very well, and the fact it can be used in significantly more ways than usual MIGS procedures, such as in closed angle glaucoma (only MIGS device that can treat that). These are all things we're yet to fully see the implications of, and therefore wouldn't typically be accounted for in models. If you just looked at the model though, you'd think MIGS was already fairly mature, rather than only now entering the growth stage